Page last updated: 2024-12-09

cinromide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID688145
CHEMBL ID93233
CHEBI ID135038
SCHEMBL ID35055
SCHEMBL ID35056
MeSH IDM0070076

Synonyms (62)

Synonym
CHEMBL93233
3-bromo-n-ethylcinnamamide, trans
58473-74-8
nsc-335304
cinromide
nsc335304
(e)-m-bromo-n-ethylcinnamamide
vumide
cinromide (usan/inn)
D03513
2-propenamide, 3-(3-bromophenyl)-n-ethyl-, (e)-
cinromide [usan:inn]
brn 2257983
2-propenamide, 3-(3-bromophenyl)-, (e)-
cinromidum [inn-latin]
(e)-3-(3-bromophenyl)-n-ethyl-2-propenamide
cinromida [inn-spanish]
trans-3-bromo-n-ethylcinnamamide, technical grade, 90%
trans-3-bromo-n-ethylcinnamamide, 99%
NCGC00164530-01
CHEBI:135038
(e)-3-(3-bromophenyl)-n-ethylprop-2-enamide
NCGC00164530-02
NCGC00164530-03
dtxsid7046417 ,
dtxcid5026417
cas-58473-74-8
tox21_112161
trans-3-bromo-n-ethylcinnamamide
69449-19-0
3-bromo-n-ethylcinnamide
3-(3-bromophenyl)-n-ethyl-2-propenamide
(2e)-3-(3-bromophenyl)-n-ethylprop-2-enamide
cinromida
cinromidum
nsc 335304
m197ke7a5n ,
unii-m197ke7a5n
bw 122u
AKOS008920173
cinromide [inn]
cinromide [usan]
cinromide [mi]
CCG-213086
SCHEMBL35055
SCHEMBL35056
tox21_112161_1
trans 3-bromo-n-ethylcinnamamide
bw-122u
(2e)-3-(3-bromophenyl)-n-ethyl-2-propenamide #
TS-03434
(e)-3-(3-bromophenyl)-n-ethylacrylamide
AB01563282_01
Z30281577
3-(3-bromophenyl)-n-ethylacrylamide
SR-01000883703-1
sr-01000883703
CS-0013054
HY-B1274
gtpl10256
mfcd00075351
Q27283342

Research Excerpts

Overview

Cinromide is a medium-extraction ratio drug with a short half-life. It is an experimental anticonvulsant currently in phase II testing.

ExcerptReferenceRelevance
"Cinromide is a medium-extraction ratio drug with a short half-life (0.92 +/- 0.23 hr) when compared with the active metabolite, which has a low extraction ratio and a longer half-life (4.43 +/- 0.76 hr)."( Pharmacokinetic relationships between cinromide and its metabolites in the rhesus monkey I: 3-Bromocinnamamide, an active metabolite.
Lane, EA; Levy, RH, 1983
)
1.26
"Cinromide is an experimental anticonvulsant currently in phase II testing. "( Differential kinetics of cinromide and two of its metabolites in epileptic patients.
Friel, PN; Lane, EA; Levy, RH; Ojemann, LM; Wilensky, AJ, 1981
)
2.01

Actions

ExcerptReferenceRelevance
"Cinromide was found to suppress generalized convulsions in small, subtoxic doses, whereas larger, sometimes toxic doses were required to suppress focal seizure activity."( The effect of cinromide on "kindled" seizures in the rat.
Bruni, J; Burnham, WM; Chiu, P; Lipnowski, S, 1982
)
1.35

Bioavailability

Incomplete oral bioavailability is a result of first-pass metabolism rather than incomplete absorption. The absorption rate of cinromide varied widely between subjects producing maximum cin romide concentrations between 0.5 and 1%.

ExcerptReferenceRelevance
" Incomplete oral bioavailability of cinromide is a result of first-pass metabolism rather than incomplete absorption."( Pharmacokinetic relationships between cinromide and its metabolites in the rhesus monkey I: 3-Bromocinnamamide, an active metabolite.
Lane, EA; Levy, RH, 1983
)
0.81
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
cinnamamidesAn enamide which is cinnamamide or a derivative of cinnamamide obtained by replacement of one or more of its hydrogens.
secondary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency30.12300.007215.758889.3584AID1224835; AID624030
RAR-related orphan receptor gammaMus musculus (house mouse)Potency10.16450.006038.004119,952.5996AID1159521; AID1159523
TDP1 proteinHomo sapiens (human)Potency23.71500.000811.382244.6684AID686978
GLI family zinc finger 3Homo sapiens (human)Potency20.22010.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency13.41670.000221.22318,912.5098AID743042; AID743053
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency18.69660.001022.650876.6163AID1224838; AID1224839; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency11.66340.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency9.43920.001530.607315,848.9004AID1224841
pregnane X nuclear receptorHomo sapiens (human)Potency26.60320.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency7.65320.000229.305416,493.5996AID1259244; AID743091
aryl hydrocarbon receptorHomo sapiens (human)Potency9.04440.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency6.68240.001723.839378.1014AID743083
histone deacetylase 9 isoform 3Homo sapiens (human)Potency30.83560.037617.082361.1927AID1259364; AID1259388
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency0.08090.005612.367736.1254AID624032
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency5.30800.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency5.30800.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (37)

Assay IDTitleYearJournalArticle
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1815486Inhibition of B0AT1 (unknown origin) by radiolabled uptake assay2021Bioorganic & medicinal chemistry letters, 12-01, Volume: 53Discovery of novel, potent and orally efficacious inhibitor of neutral amino acid transporter B
AID1815509Inhibition of B0AT1 (unknown origin) by FLIPR assay2021Bioorganic & medicinal chemistry letters, 12-01, Volume: 53Discovery of novel, potent and orally efficacious inhibitor of neutral amino acid transporter B
AID227700Anticonvulsant activity2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-199016 (55.17)18.7374
1990's0 (0.00)18.2507
2000's1 (3.45)29.6817
2010's4 (13.79)24.3611
2020's8 (27.59)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.29 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index5.52 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (10.00%)5.53%
Reviews1 (3.33%)6.00%
Case Studies1 (3.33%)4.05%
Observational0 (0.00%)0.25%
Other25 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]